Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.
DOI:
10.1200/jco.2025.43.5_suppl.134
Publication Date:
2025-02-18T14:35:11Z
AUTHORS (15)
ABSTRACT
134 Background: Prostate cancer patients with visceral metastases at diagnosis are often treated using one-size-fits-all approach. For example, CHAARTED criteria treats any metastasis as high volume. Therefore, we aimed to assess overall survival (OS) by site of involvement in metastatic PCa. Methods: Surveillance, Epidemiology, and End Results (SEER) database (2010-2021) was queried obtain case listing data on PCa from 17 registries. The were categorized into three groups based diagnosis: lung metastasis, liver others. Kaplan-Meier analysis performed estimate median OS 95% confidence interval (CI). Log-rank test conducted if significantly different among the groups. Cox proportional hazard regression magnitude difference P-value <0.05 established statistical significance. Results: This included 21,007 (lung: n=319; liver: n=123; brain: 107; bone: 20538). Metastatic population exhibited a 60 months (95% CI: 48-72) compared 24 12-36) 36 36-36) other metastases. statistically significant (p < 0.001). Compared those (HR: 1.91; 1.41-2.57) but not (1.16; 0.97-1.39) had worse adjusting for Gleason score, PSA race (Table). Conclusions: In PCa, lung-only have better should be considered differently prognostication Consideration is critical treatment intensification decisions. Limitations this include lack accounting confounding relationships individual patient level. Variable Hazard Ratio CI) Metastases (Lung) REFERENCE (Liver) 1.91 (1.41-2.57) (Other) 1.16 (0.97-1.39) score≥8 score <8 0.68 (0.64 -0.72) - ng/dL 1.01 (1.00 – 1.01) Race (White) (Black) 0.99 (0.94 1.05) (Asian or Pacific Islander) 0.70 0.76)
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....